United Therapeutics (UTHR) Tops Q2 EPS Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall St rises as oil falls heading into US midterm elections
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 6% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
United Therapeutics (UTHR) PT, Estimate Raised at BMO Capital
July 29, 2014 3:44 PM EDTBMO Capital analyst Jim Birchenough reiterated an Outperform rating and boosted his price target on United Therapeutics Corp. (NASDAQ: UTHR) to $165.00 (from $150.00) following strong Q2 results.
"We maintain our Outperform rating on shares of UTHR following review of 2Q14 results. With above-consensus... More



